Short TE proton MRS and neurofibromatosis type 1 intracranial lesions

Journal of Computer Assisted Tomography

Volumn 23, Issue 6, 1999, Pages 994-1003

  Norfray, Joseph F ^a,e   Darling, Crystal ^a   Byrd, Sharon ^a   Ross, Brian D ^d   Schwalm, Cheryl ^c   Miller, Rebecca ^b   Tomita, Tadanori ^a  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b AMERICAN MEDICAL ASSOCIATION   (United States)

^c Columbia Olympia Flds O ^*  (United States)

^d HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^e Chicago Northside MRI Center   (United States)

Author keywords

Brain, neoplasms; Magnetic resonance imaging; Magnetic resonance spectroscopy (MRS)

Indexed keywords

MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR BIOLOGY; PATHOLOGY; TUMORS;

ADDED VALUES; BRAIN NEOPLASMS; HAMARTOMA; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR GENETICS; NEUROCHEMICALS; NEUROFIBROMATOSIS TYPE 1; PROTON MAGNETIC RESONANCE SPECTROSCOPIES; SPECTRA'S; WHITE MATTER;

MAGNETIC RESONANCE IMAGING;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; HAMARTOMA; HUMAN; NEUROCHEMISTRY; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL PROCESSING; TUMOR GROWTH;

EID: 0032747348     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004728-199911000-00033     Document Type: Article

References (41)

1. Metheny LJ, Cappione AJ, Skuse GR. Genetic and epigenetic mechanisms in the pathogenesis of neurofibromatosis type 1. J Neuropathol Exp Neurol 1995;54:753-60.
2. Shen MH, Harper PS, Upadhyaya M. Molecular genetics of neurofibromatosis type 1. J Med Genet 1996;33:2-17.
3. Daston MM, Scrable H, Nordlund M, Sturbaum AK, Nissen LM, Ratner N. The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, schwann cells and oligodendrocytes. Neuron 1992;8:415-28.
4. Weinberg R. Tumor suppressor genes. Neuron 1993;11:191-6.
5. Jessell TM. Adhesion molecules and the hierarchy of neural development. Neuron 1988;1:3-13.
6. Mikol DD, Stefansson K. A phosphatidylinosiol-linked peanut agglutinin-binding glycoprotein in central nervous system myelin and on oligodendrocytes. J Cell Biol 1988;106:1273-9.
7. Viskochil D, Cawthon R, O'Connell P, et al. The gene encoding the oligodendrocyte-myelin glycoprotein is embedded within the neurofibromatosis type 1 gene. Mol Cell Biol 1991;1:906-12.
8. Easton DF, Ponder MA, Huson SN, Ponder AJ. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet 1993;53:305-13.
9. Barkovich AJ. The phakomatoses. In: Barkovich AJ, ed. Pediatric neuroimaging. New York: Raven Press, 1995:272-92.
10. Byrd SE. Central nervous system manifestations of inherited syndromes. In: Atlas SW, ed. Magnetic resonance imaging of the brain and spine. New York: Raven Press, 1991:540-9.
11. Smirniotopoulos JG, Murphy FM. Central nervous system manifestations of the phakomatoses and other inherited syndromes. In: Atlas SW, ed. Magnetic resonance imaging of the brain and spine. Philadelphia: Lippincott-Raven, 1996:773-81.
12. Itoh T, Magnaldi S, White RM, et al. Neurofibromatosis type 1: the evaluation of deep gray and white matter MR abnormalities. AJNR 1994;15:1513-9.
13. Sevick RJ, Barkovich AJ, Edwards MSB, Koch T, Bérg B, Lempert T. Evaluation of white matter lesions in neurofibromatosis type 1: MR findings. AJR 1992;159:171-5.
14. Terada H, Barkovich AJ, Edwards MSB, Ciricillo SF. Evaluation of high-intensity basal ganglia lesions on T1-weighted MR in neurofibromatosis type 1. AJNR 1996;17:755-60.
15. Elster AD. Radiologie screening in the neurocutaneous syndromes: strategies and controversies. AJNR 1992;13:1078-82.
16. Imes RK, Hoyt WF. Childhood chiasmal gliomas: update on the fate in the 1969 San Francisco study. Br J Ophthalmol 1986;70: 179-82.
17. Leisti E, Phytinen J, Poyhonen M. Spontaneous decrease of a pilocytic astrocytoma in neurofibromatosis type 1. AJNR 1996;17: 1691-4.
18. Parazzini C, Triulzi F, Bianchini E, et al. Spontaneous involution of optic pathway lesions in neurofibromatosis type 1: serial contrast MR evaluation. AJNR 1995;16:1711-8.
19. Danielsen ER, Ross B. Basic physics of MRS. In: Danielsen ER, Ross B, eds. Magnetic resonance spectroscopy diagnosis of neurological diseases. New York: Marcel Dekker, 1999:5-22.
20. Kohler S. PROBE/SV: single-voxel proton brain exam applications guide. Milwaukee: General Electric, 1993.
21. Kreis R, Ross BD. Cerebral metabolic disturbances in patients with subacute and chronic diabetes mellitus: detection with proton MR spectroscopy. Radiology 1992;184:123-30.
22. Ross B, Michaelis T. Clinical application of magnetic resonance spectroscopy. Magn Res Q 1994;10:191-247.
23. Jackson EF, Doyle TJ, Wolinsky JS, Narayana PA. Short TE hydrogen-1 spectroscopic MR imaging of normal human brain: reproducibility studies. J Magn Res Imag 1994;4:545-51.
24. Webb PG, Sailasuta N, Kohler SJ, Raidy T, Moats RA, Hurd RE. Automated single-voxel proton MRS: technical development and multisite verification. Magn Res Med 1994;31:365-73.
25. Alberts BM, Stein WD, Laskey RA, Bernfield MR, Staehelin LA, Slack JMW. Cells: their structure and function. In: McHenry R, ed. The new encyclopaedia Britannica, vol. 15. Macropaedia. Chicago: Encyclopaedia Britannica, 1993:565-93.
26. Ruiz-Cabello J, Cohen JS. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed 1992;5:226-33.
27. DeStefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Res Med 1995;34: 721-7.
28. 31P MRS observations of tumor energy metabolism. NMR Biomed 1992;5:279-89.
29. Veech RL. The metabolism of lactate. NMR Biomed 1991;4:53-8.
30. Berridge MJ. Inositol lipids and cell proliferation. Biochim Biophys Acta 1987;907:33-45.
31. 1H spectroscopy. Glutamate and glutamine; myo-inositol and related metabolites. NMR Biomed 1991;4:59-63.
32. Fulham MJ, Bizzi A, Dietz MJ, et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 1992;185:675-86.
33. Castillo M, Green C, Kwock L, et al. Proton MR spectroscopy in patients with neurofibromatosis type 1: evaluation of hamartomas and clinical correlation. AJNR 1995;16:141-7.
34. DiPaolo DP, Zimmerman RA, Rorke LB, Zackai EH, Bilaniuk LT, Yachis AT. Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain. Radiology 1995;195:721-4.
35. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
36. Snustad P, Simmons MJ, Jenkins JB. Gene regulation in eukaryotes and the genetic basis of cancer. In: Snustad P, Simmons MJ, Jenkins JB, eds. Principles of genetics. New York: Wiley, 1997: 572-604.
37. Louis DN. the p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 1994;53:11-21.
38. ras contributes to malignant tumor growth in von Recklinghausen (type-1) neurofibromatosis. Cell 1992;69: 265-73.
39. Gutmann DH, Giordano MJ, Mahado DK, Lau N, Silbergeld D, Guha A. Increased neurofibromatosis 1 gene expression in astrocytic tumors: positive regulation by p21-ras. Oncogene 1996;11: 2121-7.
40. Platten M, Giordano MJ, Dirven CM, Gutmann DH, Louis DN. Up-regulation of specific NF1 gene transcripts in sporadic pilocytic astrocytomas. Am J Pathol 1996;149:621-7.
41. von Deimling A, Louis DN, Menon AG, et al. Deletions on the long arm of chromosome 17 in pilocytic astrocytoma. Acta Neuropathol 1993;86:81-5.